# Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

> **NCT03861702** · PHASE2 · COMPLETED · sponsor: **Nelson Yee** · enrollment: 28 (actual)

## Conditions studied

- Locally Advanced Pancreatic Carcinoma(LAPC)

## Interventions

- **DRUG:** FOLFOX regimen
- **DRUG:** Liposomal Irinotecan

## Key facts

- **NCT ID:** NCT03861702
- **Lead sponsor:** Nelson Yee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-02
- **Primary completion:** 2023-08-16
- **Final completion:** 2024-09-27
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03861702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03861702, "Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03861702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*